Pryor Cashman client Marina Biotech, Inc. (OTCQB: MRNA), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, announced on February 7 that it has entered into a license agreement regarding Marina's SMARTICLES^TM platform for the delivery of nanoparticles including small molecules, peptides, proteins and biologics. The license provides for up to $90MM in success-based milestones.

News of this deal was also featured in Yahoo Finance. 

The Pryor Cashman Team

Representing Marina on the transaction were Larry Remmel and Michael Campoli, both members of Pryor Cashman’s nationally-recognized Corporate Group.